Back to your search result

Description

A potent, reversible, competitive, and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38beta (Ki = 16 nM, IC50 = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2, IC50 = 280 nM). Blocks LPS-induced TNF-alpha and interleukin biosynthesis. Reported to induce LDL receptor expression in Hep52 cells. A 1 mg/ml solution of SB 202190 (Cat. No. 559397) in anhydrous DMSO is also available., A potent, reversible, competitive, and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38beta (Ki = 16 nM, IC50 = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2, IC50 = 280 nM). Blocks LPS-induced TNF-alpha and interleukin biosynthesis. Reported to induce LDL receptor expression in Hep52 cells.